Nuveen Asset Management, LLC Glycomimetics Inc Transaction History

Nuveen Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $2.29 Million - $3.37 Million	-1,059,121 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.89 - $4.22 $1.93 Million - $2.82 Million	668,527 Added 171.16%	1,059,121 $3.19 Million
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $129,779 - $204,558	48,245 Added 14.09%	390,594 $1.47 Million
Q3 2020 Nov 16, 2020	BUY	$3.07 - $5.0 $582,072 - $948,000	189,600 Added 124.13%	342,349 $1.05 Million
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $41,253 - $75,297	20,026 Added 15.09%	152,749 $575,000
Q1 2020 May 14, 2020	SELL	$1.83 - $5.41 $2,247 - $6,643	-1,228 Reduced 0.92%	132,723 $302,000
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $21,952 - $100,744	-7,840 Reduced 5.53%	133,951 $577,000
Q2 2019 Aug 15, 2019	BUY	$10.6 - $13.12 $1.5 Million - $1.86 Million	141,791 New	141,791 $1.69 Million

17.6M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.